Welcome to our dedicated page for VTEX SEC filings (Ticker: VTEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VTEX (NYSE: VTEX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. VTEX files annual reports on Form 20-F and interim reports on Form 6-K, which are prepared in accordance with U.S. GAAP and the rules and regulations of the U.S. Securities and Exchange Commission. These filings contain condensed consolidated interim financial statements, management’s discussion and analysis of financial condition and results of operations, and other information relevant to shareholders and analysts.
In its 6-K filings, VTEX presents condensed consolidated interim balance sheets, statements of operations, statements of changes in shareholders’ equity, and statements of cash flows. The company discloses subscription revenue, services revenue, total revenue, cost of revenue, gross profit, operating expenses, and net income attributable to controlling shareholders. It also reports key non-GAAP metrics such as non-GAAP subscription gross profit, non-GAAP income from operations, non-GAAP net income, and non-GAAP free cash flow, along with commentary on business outlook and share repurchase activity.
The notes to the financial statements describe the nature of VTEX’s business as a provider of a software-as-a-service digital commerce platform tailored for enterprise brands and retailers. They also outline the basis of presentation, consolidation of subsidiaries in multiple countries, and significant accounting policies and estimates. Additional 6-K filings include press releases on topics such as Black Friday–Cyber Monday GMV performance, technology initiatives, and commercial highlights.
On Stock Titan, VTEX filings are updated as new documents are released to the SEC’s EDGAR system. AI-powered summaries help explain the contents of lengthy filings by highlighting revenue composition, profitability, cash flow trends, and operational themes such as AI-connected commerce, omnichannel capabilities, and B2B and B2C platform usage. Users can review these filings to understand VTEX’s financial position, results of operations, and strategic direction as disclosed in its official regulatory documents.
VTEX insider plans a small share sale under Rule 144. A holder of VTEX Class A common stock filed a notice to sell 4,808 shares through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate aggregate market value of $19,953.20 and 103,947,244 Class A shares outstanding. The shares being sold were originally acquired as founder stock on 11/02/2021 for cash. The filer also reports a prior sale during the past three months, where ITACARE CORPORATION sold 4,808 Class A shares on 11/26/2025 for gross proceeds of $19,232.00. The signer represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
VTEX reported a planned insider sale under Rule 144. A holder has filed to sell up to 67,926 shares of common stock through broker Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $281,926.86. The filing notes that 103,947,244 shares of common stock were outstanding at the time stated; this is a baseline figure, not the amount being sold.
The shares to be sold were acquired through a mix of restricted stock vesting under a registered plan on several dates in 2024 and earlier private acquisitions from the issuer or an affiliate in 2019 and 2020. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about VTEX’s current or prospective operations.
VTEX has a holder filing a notice of proposed sale under Rule 144 for 32,414 shares of common stock, with an aggregate market value of $133,720.72. These shares are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 12/01/2025. The issuer has 178,035,595 shares of common stock outstanding, providing context for the size of this planned sale.
The shares to be sold were acquired as restricted stock directly from the issuer on 11/01/2024 and 02/01/2025 in four grants of 11,445, 1,907, 11,437, and 7,625 shares, all noted as "Not Applicable" for cash payment, consistent with stock-based awards. The person on whose behalf the sale is planned represents that they do not know of any undisclosed material adverse information about VTEX.
A VTEX shareholder filed a Form 144 notice indicating an intent to sell up to 9,616 shares of common stock, with an aggregate market value of $38,560.16. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE, and the filing notes that 103,947,244 common shares are outstanding. The seller acquired these 9,616 shares as founder shares from the issuer on 10/25/2021.
The notice also lists prior sales over the last three months under a Rule 10b5-1 trading program for MIRA LIMITED, including one transaction of 4,808 common shares on 11/10/2025 for $19,236.81. By signing the form, the seller represents that they are not aware of any undisclosed material adverse information about VTEX’s current or prospective operations.
VTEX shareholder Signo Inv. Tech Co. Ltd filed a Form 144 indicating a proposed sale of 9,616 shares of common stock through Morgan Stanley Smith Barney on the NYSE. The shares have an aggregate market value of $38,560.16 and are part of a class with 103,947,244 shares outstanding. The securities were acquired as founder shares on 10/25/2019. Over the prior three months, the same holder executed multiple Rule 10b5-1 sales of 4,808 shares each between August 18 and November 10, 2025, with individual gross proceeds ranging from about $19,347.87 to $22,164.88. The signer certifies they are not aware of undisclosed material adverse information about VTEX.
VTEX reported Q3 results showing steady top-line growth and stronger profitability. Total revenue was $59.6 million (up 6.5% year over year), driven by higher transaction activity as GMV reached $5.0 billion (up 13.1%). Subscription revenue rose to $58.4 million, while services revenue declined to $1.2 million as the company phased out hyper-care implementations.
Gross profit increased to $46.1 million, lifting gross margin to 77.3% from 74.4%, helped by efficiencies in support. Operating income improved to $4.2 million and net income doubled to $6.4 million, with diluted EPS of $0.034. Year to date, operating cash flow strengthened to $22.1 million, aided by lower receivables. The company executed a share repurchase of $37.8 million year to date and subsequently canceled 1,817,461 Class A shares in October. R&D expense increased as VTEX invested in product and IT, while G&A and S&M were stable.
Cash and cash equivalents were $20.4 million and marketable securities $182.1 million as of September 30, 2025, supporting continued investment and operations.
VTEX (NYSE: VTEX) reported Q3 2025 results with GMV of US$5.0 billion (up 13.1% YoY) and total revenue of US$59.6 million (up 6.5%). Subscription revenue was US$58.4 million, 98% of total, rising 8.4%. Profitability improved: non-GAAP subscription gross margin reached 80.2%, non-GAAP income from operations was US$9.5 million (16% margin), and non-GAAP net income was US$10.6 million (18% margin). Non-GAAP free cash flow was US$7.5 million.
The company reduced headcount to 1,234 as of September 30, 2025. VTEX repurchased 4.5 million Class A shares at an average US$4.14 for US$18.8 million, bringing cumulative buybacks to 20.5 million shares for US$96.6 million. For Q4 2025, VTEX targets FX-neutral subscription revenue growth of 5.0%–10.0% (implying US$65.8–US$68.8 million), with a non-GAAP income from operations margin in the mid‑twenties and free cash flow margin in the high‑teens. For full-year 2025, VTEX targets FX-neutral subscription revenue growth of 9.3%–10.7% (implying US$234–US$237 million).
VTEX Form 144 notice: The filer proposes to sell 4,500 shares of VTEX common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $18,630.00. The securities were acquired on 03/19/2019 through previously exercised stock options and were paid for in cash.
The filing shows the approximate date of sale as 09/16/2025 on the NYSE. Recent related transactions disclosed include multiple Rule 10b5-1 sales during July and August 2025 totaling 9,000 shares with gross proceeds reported for each sale.
Form 144 notice for VTEX (VTEX) indicates a proposed sale of 4,500 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $18,630.00 and an approximate sale date of 09/16/2025. The shares were acquired on 03/19/2019 by previously exercised stock options and paid in cash. The filing lists prior 10b5-1 plan sales by related parties totaling 9,000 shares in July and August 2025 with accompanying gross proceeds shown. The notice includes the standard Rule 144 representation about material nonpublic information and 10b5-1 plan adoption disclosure.
VTEX Form 144 summary reports a proposed sale of 65,489 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $282,257.59. The securities were acquired as Restricted Stock Units from the issuer on 10/25/2021 and the planned approximate sale date is shown as 08/11/2025 on the NYSE.
The filing also lists 14 prior trades executed under a 10b5-1 plan between 05/12/2025 and 08/06/2025, totaling 104,426 shares sold, and shows 103,947,244 shares outstanding. The filer certifies they do not possess undisclosed material adverse information at the plan adoption or instruction date.